Product Images Eslicarbazepine Acetate
View Photos of Packaging, Labels & Appearance
- 51407-779-30LB - Eslicarbazepine Acetate 200mg - Rev. 0725.jpg - 51407 779 30LB Eslicarbazepine Acetate 200mg Rev. 0725
- 51407-780-30LB - Eslicarbazepine Acetate 400mg - Rev. 0725.jpg - 51407 780 30LB Eslicarbazepine Acetate 400mg Rev. 0725
- 51407-781-60LB - Eslicarbazepine Acetate 600mg - Rev. 0725.jpg - 51407 781 60LB Eslicarbazepine Acetate 600mg Rev. 0725
- 51407-782-30LB - Eslicarbazepine Acetate 800mg - Rev. 0725.jpg - 51407 782 30LB Eslicarbazepine Acetate 800mg Rev. 0725
- Figure1.jpg - Figure1
- Figure2.jpg - Figure2
- Figure3a.jpg - Figure3
- Figure3b.jpg - Figure3b
- Figure4.jpg - Figure4
- Figure5.jpg - Figure5
- Structure.jpg - Structure
Product Label Images
The following 11 images provide visual information about the product associated with Eslicarbazepine Acetate NDC 51407-782 by Golden State Medical Supply, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
51407-779-30LB - Eslicarbazepine Acetate 200mg - Rev. 0725.jpg - 51407 779 30LB Eslicarbazepine Acetate 200mg Rev. 0725
This is the product information for a medication called Eslicarbazapine acetate in tablet form, with each tablet containing 200 mg of the active ingredient. The dosage instructions and storage information are provided, including keeping the tablets in a tight container, away from children at a temperature range between 20°C to 25°C (68°F to 77°F). The medication is prescribed by a healthcare provider and it is important to refer to the package insert for further details. The medicine is distributed by GSMS, Inc in Camarillo, California.*
51407-780-30LB - Eslicarbazepine Acetate 400mg - Rev. 0725.jpg - 51407 780 30LB Eslicarbazepine Acetate 400mg Rev. 0725
This text provides information about a medication called Eslicarbazepine tablets, with a dosage of 400mg. It includes instructions to keep the tablets in a tight container, store them between 15°C to 30°C, and dispense them with the Medication Guide for each patient. The text also mentions a website for more information and indicates it is marketed in the USA.*
51407-781-60LB - Eslicarbazepine Acetate 600mg - Rev. 0725.jpg - 51407 781 60LB Eslicarbazepine Acetate 600mg Rev. 0725
51407-782-30LB - Eslicarbazepine Acetate 800mg - Rev. 0725.jpg - 51407 782 30LB Eslicarbazepine Acetate 800mg Rev. 0725
This text provides information about Eslicarbazepine Acetate Tablets, with each tablet containing 800 mg of the active ingredient. It includes directions for use, storage recommendations, dosage information, and manufacturer details. The NDC number for the product is 51407-782-30. This medication is typically taken once daily as indicated in the package insert.*
Figure2.jpg - Figure2
This appears to be a report on fold change and 908 cycle threshold in relation to a specific study or experiment. The text suggests a recommendation for a higher dose of elicarbazepine or primidone.*
Figure3b.jpg - Figure3b
This text discusses changes in fold change and provides recommendations related to the use of statins, oral contraceptives, and other drugs. It mentions adjusting the dose of simvastatin and rosuvastatin based on clinically significant changes in lipid levels. It also suggests considering additional or alternative non-hormonal birth control methods. It emphasizes the importance of monitoring patients to maintain lipid levels.*
Figure5.jpg - Figure5
This text describes the reduction in seizure frequency from baseline for Esucarbazepine Acetate tablets 1200mg. The study also mentions the comparison with a placebo group in the study.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.